Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 112.5% in January

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 31st total of 3,200 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is presently 0.4 days.

Adlai Nortye Stock Performance

NASDAQ ANL traded up $0.01 during mid-day trading on Wednesday, hitting $2.11. The company's stock had a trading volume of 7,228 shares, compared to its average volume of 12,768. The company's 50 day simple moving average is $2.21 and its 200 day simple moving average is $2.48. Adlai Nortye has a twelve month low of $1.85 and a twelve month high of $17.48.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.